NO830210L - Tabletter som ikke skader spiseroeret. - Google Patents
Tabletter som ikke skader spiseroeret.Info
- Publication number
- NO830210L NO830210L NO830210A NO830210A NO830210L NO 830210 L NO830210 L NO 830210L NO 830210 A NO830210 A NO 830210A NO 830210 A NO830210 A NO 830210A NO 830210 L NO830210 L NO 830210L
- Authority
- NO
- Norway
- Prior art keywords
- carbonate
- tablets
- tablet
- tablets according
- granulation
- Prior art date
Links
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 239000001569 carbon dioxide Substances 0.000 claims description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 7
- 229960004082 doxycycline hydrochloride Drugs 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 238000007908 dry granulation Methods 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 2
- 229940072172 tetracycline antibiotic Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 26
- 210000003238 esophagus Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- UVKFSMBPRQBNCH-UHFFFAOYSA-M 4,4-diphenylbutan-2-yl-ethyl-dimethylazanium;bromide Chemical compound [Br-].C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 UVKFSMBPRQBNCH-UHFFFAOYSA-M 0.000 description 1
- -1 Alkaline earth metal carbonates Chemical class 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI811677 | 1981-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO830210L true NO830210L (no) | 1983-01-24 |
Family
ID=8514443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO830210A NO830210L (no) | 1981-06-01 | 1983-01-24 | Tabletter som ikke skader spiseroeret. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0079928B1 (da) |
| JP (1) | JPS58500949A (da) |
| DD (1) | DD202503A5 (da) |
| DE (1) | DE3270579D1 (da) |
| DK (1) | DK158563C (da) |
| ES (1) | ES511731A0 (da) |
| FI (1) | FI83475C (da) |
| IT (1) | IT8221516A0 (da) |
| NO (1) | NO830210L (da) |
| PT (1) | PT74830B (da) |
| WO (1) | WO1982004191A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837030A (en) * | 1987-10-06 | 1989-06-06 | American Cyanamid Company | Novel controlled release formulations of tetracycline compounds |
| JP2523384B2 (ja) * | 1990-02-02 | 1996-08-07 | エスエス製薬株式会社 | 発泡性製剤組成物 |
| WO2005046651A1 (en) * | 2003-11-12 | 2005-05-26 | Ranbaxy Laboratories Limited | Liquid filled capsules of doxycycline |
| CN100340241C (zh) * | 2004-06-28 | 2007-10-03 | 中山大学中山眼科中心 | 一种滴眼液及其制备方法与用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1962015C3 (de) * | 1969-12-11 | 1980-07-03 | Uzina De Medicamente Bucuresti, Bukarest | Verfahren zur Herstellung von Tabletten mit raschem Zerfall |
| GB1380741A (en) * | 1971-02-05 | 1975-01-15 | Squibb & Sons Inc | Antibiotic compositions and their preparation |
| CA982478A (en) * | 1971-04-12 | 1976-01-27 | Jerome Berk | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
| GB1390683A (en) * | 1972-12-18 | 1975-04-16 | Biorex Laboratories Ltd | Pharmaceutical composition |
| GB1401360A (en) * | 1972-12-18 | 1975-07-16 | Biorex Laboratories Ltd | Pharmaceutical composition |
-
1982
- 1982-04-27 ES ES511731A patent/ES511731A0/es active Granted
- 1982-04-30 PT PT74830A patent/PT74830B/pt unknown
- 1982-05-27 IT IT8221516A patent/IT8221516A0/it unknown
- 1982-05-27 DD DD82240230A patent/DD202503A5/de unknown
- 1982-05-28 DE DE8282901785T patent/DE3270579D1/de not_active Expired
- 1982-05-28 JP JP57501814A patent/JPS58500949A/ja active Pending
- 1982-05-28 EP EP82901785A patent/EP0079928B1/en not_active Expired
- 1982-05-28 WO PCT/FI1982/000019 patent/WO1982004191A1/en active IP Right Grant
-
1983
- 1983-01-14 DK DK013883A patent/DK158563C/da not_active IP Right Cessation
- 1983-01-24 NO NO830210A patent/NO830210L/no unknown
- 1983-01-31 FI FI830327A patent/FI83475C/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI830327A0 (fi) | 1983-01-31 |
| FI83475C (fi) | 1991-07-25 |
| PT74830B (en) | 1983-11-30 |
| ES8307096A1 (es) | 1983-07-01 |
| IT8221516A0 (it) | 1982-05-27 |
| EP0079928B1 (en) | 1986-04-16 |
| DK158563B (da) | 1990-06-11 |
| DK13883D0 (da) | 1983-01-14 |
| ES511731A0 (es) | 1983-07-01 |
| WO1982004191A1 (en) | 1982-12-09 |
| EP0079928A1 (en) | 1983-06-01 |
| JPS58500949A (ja) | 1983-06-09 |
| DE3270579D1 (en) | 1986-05-22 |
| FI830327L (fi) | 1983-01-31 |
| FI83475B (fi) | 1991-04-15 |
| PT74830A (en) | 1982-05-01 |
| DK158563C (da) | 1990-11-12 |
| DD202503A5 (de) | 1983-09-21 |
| DK13883A (da) | 1983-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5132721B2 (ja) | ＨＭＧ−ＣｏＡ還元酵素阻害剤の徐放性改良製剤 | |
| AU618020B2 (en) | Covered retard forms | |
| CA2058946C (en) | Formulations for the oral administration of drugs with masked taste | |
| Dehghan et al. | Gastroretentive drug delivery systems: A patent perspective | |
| RU2385154C2 (ru) | Составы и способы подавления секреции желудочного сока | |
| JP4637338B2 (ja) | シロスタゾール有核錠 | |
| US20020119196A1 (en) | Texture masked particles containing an active ingredient | |
| RU2602911C2 (ru) | Фармацевтическая композиция, содержащая кальциевую соль розувастатина | |
| HUT75158A (en) | Oral pharmaceutical compositions for selective release of drug in the colon, and process for producing them | |
| JP2004501190A (ja) | 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 | |
| PT85213B (pt) | Processo para a preparacao de composicoes farmaceuticas de libertacao prolongada para administracao oral contendo um polimero celusosico | |
| JP2000516222A (ja) | 嚥下が容易な経口医薬組成物 | |
| CA2456976A1 (en) | Expandable gastric retention device | |
| EP2523654A2 (en) | Immediate release compositions of acid labile drugs | |
| NO830210L (no) | Tabletter som ikke skader spiseroeret. | |
| JP2011520868A (ja) | 胃酸分泌を阻害するための組成物および方法 | |
| CZ370298A3 (cs) | Draselné, sodné a trisoxaprozinové soli farmaceutických formulací | |
| WO2005018618A1 (en) | Formulation of stable for moisture absorption and quickly dissolved tablet containing cefuroxime axetil and it's manufacturing process | |
| Kishorebabu et al. | A review on floating drug delivery system | |
| KR0171413B1 (ko) | 젬피브로질 제제 | |
| US5281421A (en) | Gemfibrozil formulations | |
| NO172834B (no) | Fremgangsmaate for fremstilling av tablett med overtrekk som inneholder poredannende substans | |
| Asif | Design and Characterization of Colon Targeted Nimesulide Double Coated Tablets for the Prophylaxis of Colon Cancer | |
| CA2044507A1 (en) | Gemfibrozil formulations | |
| IE852069L (en) | Sustained release tablets |